AmoyDx® PD-L1 (E1L3N) assay gained the priority recommendation from Chinese expert consensus
The AmoyDx® PD-L1 (E1L3N) assay (NMPA approval number 20223400313) was prioritized as companion diagnostics for Pembrolizumab.
AmoyDx has successfully held the 2023 Distributors Annual Meeting at the headquarter in Xiamen, China, on January 22-23, 2024
The 2023 Distributors Annual Meeting has been successfully hosted at the headquarter in Xiamen, China, on January 22-23, 2024. The event, attended by overseas colleagues and distributors worldwide, achieved notable success and provided a platform for a fo
LC-SCRUM's 10-Year Milestone: Amoy Diagnostics Earns International Recognition for Excellence
Dr. Limou Zheng, Founder of Amoy Diagnostics, and Mr. Frank Zheng, Chief Operating Officer, were invited to give a keynote speech at the 10th-anniversary conference of the Asian Lung Cancer Genome Screening Project (LC-SCRUM).
Highlights of China International Import Expo (CIIE) 2023 - Amoy Diagnostics Announced Multiple Collaborations with AstraZeneca and Pfizer
AmoyDx announced multiple collaborations with AstraZeneca and Pfizer during the 2023 China International Import Expo (CIIE), held on November 5-10 in Shanghai China. These partnerships aim to jointly promote the development of precision diagnostics
AmoyDx® Microsatellite Instability (MSI) Detection Kit Received NMPA Approval for Pan-Tumor Immunotherapy Companion Diagnostics
National Medical Products Administration (NMPA) granted approval to AmoyDx® Microsatellite Instability (MSI) Detection Kit
Meet us at ESMO 2023
AmoyDx is excited to be part of this incredible gathering for oncology community.
* Required information
Manage your account info
Change your password